Khidiyatova, I.M.,
Saifullina, E.V.,
Karunas, A.S.,
Akhmetgaleyeva, A.F.,
Kutlubaeva, R.F.,
Smakova, L.A.,
Lobov, S.L.,
Polyakov, A.V.,
Shchagina, O.A.,
Kadnikova, V.A.,
Ryzhkova, O.P.,
Magzhanov, R.V. (2022) predominant lesion of the pyramidal tract. The autosomal dominant form of
SPG3A, associated with mutations
Nazarova, Liliia Sh.,
Danilko, Ksenia V.,
Malievsky, Viktor A.,
Karimov, Denis O.,
Bakirov, Akhat B.,
Viktorova, Tatyana V. (2022) the polymorphic loci of immune response mediator
genes (TNFA rs1800629, LTA rs909253, IL1B rs16944, IL2-IL21 rs
Mingazheva, E.T.,
Prokofyeva, D.S.,
Valova, Ya.V.,
Andreeva, E.A.,
Nurgalieva, A.Kh.,
Valiev, R.R.,
Ekomasova, N.V.,
Faishanova, R.R.,
Romanova, A.R.,
Khusnutdinova, E.K. (2022) The high risk of ovarian cancer is primarily associated with mutations in BRCA1 and BRCA2
genesIvanova, E.,
Asadullina, D.,
Rakhimov, R.,
Izmailov, A.,
Izmailov, Al.,
Gilyazova, G.,
Galimov, Sh.,
Pavlov, V.,
Khusnutdinova, E.,
Gilyazova, I. (2022) expression level in ccRCC patients with CTCAE grade 3–
4 (M±SEM 1.71 ± 0.13) compared to CTCAE grade 0–2 group
Yanchao, L.,
Sibin, Z.,
Gareev, I.,
Huan, X.,
Junfei, Z.,
Chunyang, L.,
Beylerli, O.,
Sufianov, A.,
Chao, Y.,
Yuyan, G.,
Xun, X.,
Ahmad, A. (2022) patients, to clarify the common
genes of both, and to identify common pathways and potential drugs
Kudoyarov, E.R.,
Karimov, D.O.,
Bakirov, A.B.,
Mukhammadieva, G.F.,
Karimova, L.K.,
Galimova, R.R. (2022) of the OGG1
gene and the severity of DNA breaks.
The study revealed adverse effects produced by the chemical
genes, HLA
genes and in the anti-inflammatory cytokine (IL-
4)
gene, polymorphisms in phospholipase
by specific mutations in the NF1
gene (causing substitutions of amino acids in neurofibromin: p.Arg1038, p
Dobrodeeva, V.S.,
Shnayder, N.A.,
Novitsky, M.A.,
Asadullin, A.R.,
Vaiman, E.E.,
Petrova, M.M.,
Limankin, O.V.,
Neznanov, N.G.,
Garganeeva, N.P.,
Nasyrova, R.F. (2022) 6837793 of the NPY5R
gene, and rs16147, rs5573, rs5574 of the NPY
gene, with metabolic disorders